INTRODUCTION
Phenylketonuria (PKU; [MIM 261600]) is an autosomal recessive inborn error of metabolism caused by deficiency of hepatic phenylalanine-4-hydroxylase (PAH; EC 1.14.16.1). The clinical phenotypes of hyperphenylalaninemia due to PAH deficiency range from classic PKU (blood Phe concentrations .1200 mm) to mild PKU (600 -1200 mm) and mild hyperphenylalaninemia (120 -600 mm). Untreated patients with classic and mild PKU can develop severe mental retardation (1) . For the better part of the past 60 years, the only treatment available was dietary Phe restriction which is a burdensome therapy often leading to malnutrition and to psychosocial complications (2, 3) . Therefore, there is an urgent need for alternative therapies (4) . Recent strategies to replace the dietary treatment comprise: tetrahydrobiopterin (BH 4 ), large neutral amino acids (LNAA), enzyme replacement therapy with PEGylated phenylalanine ammonia lyase (PEG-PAL) and gene therapy. LNAA compete with phenylalanine for transport across the blood brain barrier via L-type amino acid transporter and thus can reduce the intracerebral Phe concentration. But to which extent it allows for diet liberalization still needs to be clarified in large clinical trials (5 -7) . Bacteria-derived PEG-PAL therapy substantially decreased blood Phe in both murine and clinical studies. Immunogenicity in the subcutaneous application and instability * To whom correspondence should be addressed. Tel: +43 6624420021224; Fax: +43 6624420021209; Email: florian.lagler@pmu.ac.at # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com against intestinal proteolysis of the oral PAL remain challenges for this approach (8 -10) . By carrying out murine studies, much progress has been made regarding gene therapy of PKU (11, 12) . For safety reasons, however, it has not yet been employed on PKU patients (13) .
A decade ago, the observation that pharmacological doses of BH 4 can restore enzyme function in a significant share of PKU patients (14) (15) (16) (17) (18) ushered in a new era. Finally, 5 years ago sapropterin dihydrochloride, which is the synthetic form of BH 4 , was market approved for the treatment of PKU by the Food and Drug Administration and the European Medicines Agency (19, 20) . However, its underlying mechanism is not fully clarified. In BH 4 -responsive PKU genotypes, BH 4 can act as a pharmacological chaperone (PC) that upon specific binding to the active site restores PAH function by structural stabilization of the misfolded PAH enzyme (17, 21, 22) . Wildtype PAH, however, is shifted from an activated labile conformation towards an inactive but stable state by BH 4 (23) . Thus, the BH 4 -induced gain of function of misfolded PAH is the outcome of a trade-off between a gain in protein stability and enzyme inhibition. Structural and biochemical studies have demonstrated that the inhibitory effects of BH 4 are induced by its interaction with the regulatory domain of PAH. The inhibitory effect is lower or missing in some BH 4 analogues, such as BH 2 or other ligands of the PAH active site (24 -27) . We therefore hypothesized that potent PC could be found by screening putative ligands of the PAH active site. This search was further motivated by the low efficacy of BH 4 in some PKU genotypes and its unfavourable pharmaceutical and pharmacological characteristics (low bioavailability, instability, costly synthesis). Pey et al. showed that putative PC for the treatment of PKU can be identified by screening 1000 commercially available molecules with an in vitro HTS (high through put screening) stability assay. However, the proof of concept for in vivo efficacy of alternative chaperones in PKU is missing so far.
Virtual screening is established as a major pillar of rational drug discovery and has led to the successful identification of numerous therapeutically relevant agents (19, 28, 29) . Therefore, we applied a shape-focused virtual screening method to identify compounds with potential to be active on PAH. This pre-selection step of molecules resulted in high odds of positive compound selection. The virtual hits were evaluated and characterized in several functional in vitro assays, and their in vivo efficacies were proved in Pah enu1 mice. This mouse model was generated by germline mutagenesis and carries the missense mutation V106A in the regulatory domain of PAH which leads to a mild hyperphenylalaninemia phenotype (30) (31) (32) (33) . Recently, it was shown that the amino acid change V106A leads to protein misfolding, instability and accelerated degradation of PAH in Pah enu1 and that BH 4 corrects this pathology (22, 34) . Thus, Pah enu1 is a mouse model of misfolding-induced PAH deficiency which is responsive to BH 4 (22) .
In conclusion, we identified two molecules chemically different from the previously reported candidates and with high potential for further drug development, one of which was twice as effective as BH 4 . This confirms our initial hypothesis and illustrates the value of our approach.
RESULTS

Shape-focused virtual screening of the National Cancer Institute compound database
The National Cancer Institute's (NCI) chemical library was screened for potential PC of hPAH. More than 115 000 compounds were screened and ranked using a shape-focused virtual screening engine, selected by visual inspection and ordered from the NCI for experimental evaluation.
BH 4 was selected as query structure for shape-focused virtual screening of the NCI structural database using ROCS (see Materials and Methods). Eighty-four candidate molecules were selected for testing based on their shape and chemical feature similarity, followed by visual inspection, considering their likelihood to be accommodated in the BH 4 -binding site Surface plasmon resonance (SPR) allows for rapid label-free characterization of interactions between the immobilized target protein and the screened small molecules in real time. This method has been used successfully in drug screening (35) . Thus, we screened the 84 in silico selected compounds in binding to mPAH using SPR. Thirteen of the aforementioned 84 tested compounds bound to the immobilized mPAH with a fast dissociation characteristic of reversible binding. Compounds showing higher affinity, saturability and reversible binding were classified as positive hits and they were included in further analysis. In order to determine the equilibrium constants, the interaction of the hits with mPAH was analysed in a concentration-dependent way until a saturation response was achieved as depicted in Figure 2 for compound 2 (2; numbers in bold will be used to indicate the compounds assigned number). Higher concentrations of the compounds that showed ambiguous binding behaviour in the initial screening were subsequently tested to discard false negatives. We selected six compounds that bound to mPAH in a reversible and specific way with affinities in the micromolar range and that belong to three different chemical clusters ( Table 1) . Three of the compounds (1, 5, 6 ) are based on a (thio)hydantoin scaffold with a short linker to a phenyl or furan moiety. Other compounds are based on uracil (2) and guanine (3, 4) scaffolds. Hydantoin derivatives can be found in phenylketonuric urine (36) and literature relates hydantoin-based compounds such as 1 to inhibitory activity on PAH (37) . Compounds related to 2 such as pyrimidines have been identified and investigated with regard to their function as cofactors of PAH (38) (39) (40) (41) .
Compound effect on mPAH intrinsic tryptophan fluorescence SPR analyses were performed with a surface immobilized protein which may be slightly different from dissolved PAH in its binding capabilities due to the non-directional attachment of the protein to the matrix after the amino-coupling step (42) . Thus, we used fluorescence spectroscopy as a second independent method to validate the SPR results in solution. Equal to human and rat homologs, the mouse PAH has three tryptophan residues partially buried in the protein structure that produceafter excitation at 295 nm-an emission maximum at 342 nm (26, 43) . The fluorescence spectra of mPAH with the test compounds were recorded. A typical compound titration curve is shown in Supplementary Material, Figure S1 . 1, 4, 5 and 6 increased the quantum yield at 342 nm in a concentration dependent and saturable way reminiscent of the effect caused by the substrate L-Phe. The increase in fluorescence intensity that accompanies activation of PAH by L-Phe mainly originates from changes in the emission of W120 (43) . It has been shown that this residue becomes more solvent-exposed in the substrate-activated enzyme due to domain movements around the hinge region R111 -T117 (44). The effect of 2 and 3 on the conformation of PAH could not be determined, as these substances show a fluorescence emission spectrum overlapping with that of PAH. Mapping the data of the fluorescence corrected curves against the compound concentration (expressed as total ligand present) and assuming a 1:1 binding, we obtained the apparent dissociation constants (Kd F ; Table 1 ). The observed increase in fluorescence intensity at 342 nm was competed and quenched by adding increasing concentrations of BH 4 (Supplementary Material, Fig. S1 ). These results confirmed the binding of 1, 4, 5 and 6 to PAH with affinity in the order of the BH 4 interaction (Kd F 0.49 + 0.04). The Kd F were one to two orders of magnitude lower than those observed in SPR experiments. This result is not surprising as proteins in solution present a higher degree of conformational flexibility than immobilized proteins.
PAH stabilization against endogenous proteolysis
The V106A amino acid change in PAH results in a reduction of PAH function caused by aberrant protein folding and consecutive accelerated protease degradation as shown for the mouse model Pah enu1 (34, 45) . BH 4 corrects this pathology by stabilizing the protein conformation (22) . We evaluated whether the identified ligands have the potential to stabilize PAHV106A. TsA201 cells were transiently transfected with plasmids encoding for PAH wild-type or PAHV106A and the cells were incubated with the compounds or control vehicle. Next, protein translation was blocked by addition of puromycin, and the compounds' effect on protein stability was assessed by immunoblotting with the corresponding antibodies. After 6 h of protein translation inhibition, PAH wildtype remained stable to proteolysis and the compounds had no significant effect on protein stability. On the contrary, 1 - These results indicate that the compounds assist in stabilizing the protein conformation against intracellular proteolysis and therefore can be regarded as potential PCs.
Recovery of the enzymatic activity of PAHV106A
As aforementioned, PAHV106A is a partially misfolded protein susceptible to proteolysis. Still maltose-binding protein (MBP) -tagged PAHV106A is a stable protein with a specific activity in the order of wild-type PAH (22) . To explore the effect of the compounds on PAHV106A, we compared the enzymatic activity of the tagged protein before and after enterokinase processing of MBP. The digestion reaction was performed after incubation of the protein with the compounds (5 -100 mm) or vehicle control (Fig. 3B ). The catalytic activity of MBP-PAHV106A was decreased almost 2-fold after cleavage with enterokinase for 1 h. sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS -PAGE) analyses and Coomassie staining of the enterokinase digestion reaction showed that the protease cuts specifically after the recognition sequence D-D-D-D-K located between MBP and PAHV106A and additionally leads to the appearance of degradation products. Pre-incubation of MBP-PAHV106A with the compounds led to retention of enzymatic activity to levels reached by the stable tagged protein in a dosedependent manner. Only 5 increased the activity to 100% at the lowest concentration tested. These results support the notion that incubation with compounds 1 -6 adjusts the enzyme conformation of PAHV106A, protecting it against non-specific proteolysis and enhances its catalytic activity as a result of it.
Cell viability
The discovery of the selected compounds was intended for their in vivo use in the Pah enu1 mouse model of PKU. For this reason, we next studied their effect on the viability of HepG2 cells. These cells were incubated with increasing concentrations of compounds as shown in Figure 3C . In all cases, low concentration of the compounds (100 mm) was well tolerated by the cells; 5 and 6 reduced cell viability at the maximum concentration tested (1 mM) by more than 50%. The data indicate that these compounds show cell toxicity at high concentrations. In contrast to the above, 1, 2 and 4 did not show any or just a low-level toxic effect (3).
In vivo efficacy on 13 C-Phe oxidation and blood Phe concentrations The 13 C-Phe oxidation rate assessed as cumulative tracer recovery within a 13 C-Phe breath test reflects the PAH activity in vivo (15, 22, 46, 47) . We used this endpoint to evaluate the in vivo efficacy of compounds 1 -6. First, Pah enu1 animals received single doses of 10 mg/g i.p. Only 1 and 2 which induced significant increases in Phe oxidation after a single dose were further tested in a 48h multiple dose trial (3 × 10 mg/g i.p.). We evaluated the effect of 1 and 2 in comparison to the vehicle used [distilled water for 1 and dimethyl sulfoxide (DMSO) for 2] as well as BH 4 10 mg/g (positive control) (Fig. 4) . The cumulative recovery was significantly increased Figure 5A . The degradation pattern of the protein was reduced by BH 4 pre-incubation, and 1 and 2 improved upon this effect. Moreover, 1 and 2 did not inhibit the protease activity per se as demonstrated in a control experiment with bovine serum albumin (BSA) (Fig. 5A, right panel) . Hereafter, we performed SPR competition-binding experiments to verify our initial assumption that the new PC should bind to the BH 4 -binding pocket and not to a different patch on the PAH surface. Binding of BH 4 to immobilized PAH at a saturating concentration (500 mm) was competed with increasing concentrations of 1 (0-300 mm) as indicated by the non-additive intensity of the observed sensorgrams with increasing compound concentration (Fig. 5B) .
We investigated the potential orientation of 1 and 2 when aligned to the protein-bound ligand conformation of BH 4 ( Fig. 5C and D ; binding mode of 3 and 6 in Supplementary Material, Fig. S2 ). Analogous to BH 4 , both compounds may maintain the water network mediating interactions with the iron and surrounding protein residues as well as the hydrophobic interactions seen for BH 4 by its acyclic substituent. The hydrogen bonding network is highly susceptible to the tautomeric form of the ligand. In these depictions, the tautomeric forms are adapted for a best-possible agreement of interaction patterns with the one observed for BH 4 .
Therefore, we can conclude that the selected compounds, similar to BH 4 , most probably bind to the cofactor-binding pocket of PAH and act as PC.
DISCUSSION
The market authorization of sapropterin dihydrochloride, which is the synthetic form of BH 4 , represents a substantial progress in PKU management as it allows for liberalization or replacement of burdensome lifelong treatment for many patients (15, 16) . However, the high costs [ 37 000-166 000 USD per adult; (50, 51) ] of this prototype PC and the low efficacy in some patients (52,53) justify a search for alternative molecules. Pey et al. (54) showed that this is a realistic aim by screening 1000 compounds with a HTS fluorescence-based stability assay. Their elegant study identified two putative PC for PKU treatment that increased stability and activity of misfolded PAH in vitro. Oral application to wild-type mice enhanced PAH activity and the level of the PAH protein in the liver. Nonetheless, a final confirmation of their efficacy in a mouse model of PKU remained elusive. Here, we report two novel PC that correct misfolding-induced loss of PAH function in the Pah enu1 PKU mouse model. Remarkably, one compound was twice as effective in increasing PAH activity and reducing blood Phe concentrations when compared with BH 4 . These results confirm the high potential of the identified molecules for further drug development to a more potent therapeutic agent than BH 4 and they also support the validity of our PC screening approach.
The discovery of PC has so far been based on the primary screening of compound libraries (1000 -50 000 molecules) for mild enzyme inhibitors (55, 56) or protein stabilizers (54, 57) . These approaches are plausible as PC act by stabilization against protein degradation and additionally most PC are mild inhibitors of the target enzyme. Furthermore, this does not limit the focus to compounds interacting with a particular site of the target. Yet most potent PCs including BH 4 are active-site ligands (55 -58) . We therefore used a structurebased 'directed' in silico search to identify putative ligands of the PAH active site. The protein-bound BH 4 conformation was extracted from the PDB entry 1j8u and used as a query for shape-focused screening of the NCI's database using ROCS. Out of more than 115 000 screened compounds, 84 potentially active molecules were selected from the top-ranked positions of the in silico hit list by visual inspection and then tested for PAH binding.
The physical interaction of the selected compounds with PAH was screened using SPR. Earlier, Flatmark et al. (59) described the binding of Phe and BH 4 to immobilized hPAH. We found equivalent patterns in the murine homolog. Thus, we used SPR to identify compounds with favourable binding characteristics. This led to the selection of 6 compounds out of 84 in silico hits, and the binding was confirmed in solution using intrinsic tryptophan fluorescence spectroscopy for 4 of the substances (2 were not eligible due to autofluorescence). Pah enu1 has previously been established as a model of BH 4 -responsive PAH deficiency (22, 46) . Its V106A exchange is located in the regulatory domain of PAH and induces misfolding, namely a conformational pre-activation, which is independent from substrate exposure (60) . This pre-activated enzyme is instable and prone to accelerated proteolytic degradation. Even though the specific activity of PAHV106A is unimpaired, the loss of functional PAH in Pah enu1 causes a mild hyperphenylalaninemic phenotype. In combination with a severe mutation (compound heterozygosity), V106A leads to an intermediate phenotype in patients (61) and mice (34, 46) equivalent to BH 4 -responsive mild PKU (46, 61) . The (24) . Correspondingly, our results indicate that the PC candidates identified follow the same mechanism: the six candidate compounds led to the restoration of the enzymatic activity of PAHV106A (Fig. 3B) , increased protein stability of PAHV106A against intracellular proteolysis (Fig. 3A) and reduced degradation of purified PAHV106A by ProteinaseK as a result of improved conformation (Fig. 5A) with 1 and 2 .
In vivo toxicity data were not available for all compounds. Thus, we examined the viability of HepG2 cells after incubation with our hits in order to exclude highly toxic compounds from in vivo testing. 5 and 6 showed toxic effects but only at rather high concentrations (.0.5 mM). This is in good agreement with the published LD50 of 5 in mice (960 mg/kg; available from http://chem.sis.nlm.nih.gov/chemidplus/direct.jsp ?regno=583-46-0; access date: 28th of June 2011) which is almost 100-fold above the dose applied in our in vivo tests. Consequently, all six compounds have been tested in vivo.
In single-dose experiments, two of the six compounds increased the PAH activity as quantified by cumulative 13 C-Phe recovery in breath tests and lowered blood Phe concentrations. In a 3-day multiple dose treatment, the response to 2 was in the range of that achieved by BH 4 and 1 was twice as effective. Notably, those compounds showing a higher in vitro activity and protein stabilization effect (3 -6) appeared to be ineffective in our in vivo model. Several pharmacokinetic features such as low uptake by hepatocytes and rapid metabolization or excretion may account for a low exposure of the target PAH to the active form of these compounds.
In conclusion, our innovative integrated in silico -in vitroin vivo approach allowed for the successful identification of novel PCs for the treatment of BH 4 -responsive PKU. The selection of molecules that lead to the stabilization of PAHV106A without relevant inhibitory effects resulted in the identification of very potent candidates. However, ligand-binding affinity can be mutation specific (17, 54, 62) . Thus, further studies will have to evaluate whether our compounds act similarly in the presence of other mutations rather than V106A. The necessary information will be provided by the future application of our test system and the identified compounds to other PAH variants; this may lead to the identification of other mutation-specific PCs that can be further developed in the sense of an individualized PKU therapy. Moreover, our approach can be applied to .25 other 'misfolding diseases' qualifying for PC treatment (22) . Figure 1A .
MATERIALS AND METHODS
Compounds
Stock solutions were either prepared in DMSO (Sigma Aldrich) or in water at a concentration of 10 mM or 50 mM depending on the solubility of the compound. All molecules tested were ordered from the NCI database, USA (63) . Compounds 1 and 2 were additionally ordered from Chemos GmbH and ABI Chem for animal experiments.
Hardware setup
Shape-focused virtual screening and protein-ligand docking were processed on an Intel Core 2 Quad Q6600 workstation with 4 × 2.4 GHz, 2 × 4 MB L2-Cache and 4 GB RAM using openSUSE 11.2 as operating system.
Shape-focused virtual screening
The NCI database was downloaded from the NCI's website (2009-08-24) and their data were edited using Pipeline Pilot Student Edition (version 6.1.5, Accelrys, San Diego, CA, USA). The library was filtered using the Organic Filter and Bad Valence Filter nodes and ionized at pH 7.0. The following property filtering was applied: number of carbon atoms .3; number of nitrogen and oxygen atoms ≤15; 140 ,molecular weight ,600, number of H-bond donors ≤8 and AlogP (16) ≤6. Conformational ensembles were calculated for the refined database using OMEGA (version 2.3.2, OpenEye, Santa Fe, NM, USA) and stored in the OpenEye binary format .oeb.gz for virtual screening.
Candidate molecules for experimental testing were selected using a shape-focused virtual screening method. The basic idea of such computational approaches is to generate a complementary image of the binding site by considering the shape of a ligand (template or query). Molecules complying with this mapping are expected to be potentially active on the particular target addressed by the template. The software package 'ROCS' ('Rapid Overlay of Chemical Structures', version 3.0.0, OpenEye) was employed for similarity-based screening of the NCI database. ROCS is one of the most established programs available and provides sound performance regarding virtual 3D similarity screening (64, 65) . The program assesses the volume overlap between two molecules by Gaussians that are parameterized according to the volume of heavy atoms. For activity of small organic molecules on a particular target, complementary properties in both shape and chemical functionalities are required. ROCS considers both aspects featuring dedicated scoring functions, the latter employing a so-called 'colour force field'. This force field is based on SMARTS patterns encoding six different chemical feature types. In this way, ROCS is able to maximize both molecular shape overlay and chemical functionality overlap. ROCS's 'ComboScore' function weighs both components equally (functions 'Shape Tanimoto' and 'Scaled Color'); they are normalized to a range from 0 to 1 and are subsequently summed up for the ComboScore. Hence, ComboScore's values range from 0 to 2 whereby 2 stands for 'best overlap possible' and 0 for 'no similarity'. BH 4 was used as template for shape-focused virtual screening. A representative query conformation was determined using OMEGA (using OMEGA's parameter '-maxconf' and set to 1). ROCS screening was performed using default settings. The hits were ranked using ComboScore.
LigandScout (version 3.0, Inte:Ligand, Vienna, Austria) was used for visualization (66, 67) .
Recombinant mouse PAH purification
Recombinant mouse PAH was expressed as a fusion protein using the pMAL system (NEB) in E. coli DH5a and purified as previously described (62) . Shortly, after a first amylose affinity chromatography step, the fusion protein was cleaved overnight with bovine enterokinase (NEB) and the tetrameric PAH protein was isolated by size-exclusion chromatography.
Surface plasmon resonance
A BiacoreX device (GE Healthcare) was used to screen the binding of small molecules to PAH under assay conditions similar to the procedure previously outlined (59) . Per assay, 15 mg of purified PAH were immobilized by the amine coupling reaction at pH 4.5 in a CM5 matrix to achieve an immobilization level of 20000 RU. The reference surface was pre-treated equally to the test surface, however, without immobilized protein. The assays were carried out at 208C with PBS running buffer at a flow of 10 ml/min. A DMSO correction was performed where necessary. Sequential 30 ml injections of each compound (25 mm) were run onto 15 mg of mPAH immobilized in a CM5-chip surface. The selection threshold for positive binding molecules was set to three times the binding signal in comparison to the noise signal typical of negative-binding compounds (68) . The integrity of the enzyme was regularly checked by comparison of the response units of BH 4 -binding before and after a set of injections. Compounds increasing the baseline signal irreversibly and those decreasing by more than 10% the control response of BH 4 (250 mm; RU 30) were discarded.
Tryptophan intrinsic fluorescence
Fluorescence measurements were performed with an LS50B spectrofluorimeter (PerkinElmer) at 258C. Tryptophan fluorescence emission spectra (300 -500 nm) were recorded with the excitation wavelength at 295 nm (slit width 7 nm). The compounds were added at the indicated concentrations to a quartz cuvette containing 590 ml of size exclusion chromatography (SEC) buffer (20 mM HEPES, pH 7.0, 200 mM NaCl). The background spectra of the compounds were recorded and subtracted from the spectra obtained at the same concentrations in the presence of 0.6 mg of purified tetrameric PAH.
Assay of PAH activity
In a 96-well plate format, 75 mg of purified recombinant MBP-PAHV106A per well in Tris -HCl buffer (pH 7.4) with 40 mm ammonium iron sulphate (II) and CaCl 2 2 mM were pre-incubated for 30 min with the compounds. Then 4 units of enterokinase were added and incubated for 1 h. PAH was 
Compound toxicity in cell culture
HepG2 cells were grown in Dulbecco's modified Eagle medium media (PAA) with 4.5 g/l glucose, 10% fetal calf serum, stable glutamine and 1% antibiotics at 378C in 5% CO 2 . In a 96-well plate, 10 4 cells per well were seeded and grown overnight. After a 6 h lasting incubation with the compounds, the Cell Counting Kit-8 (CCK-8; Sigma Aldrich) was added to the media and incubated at 378C. The colour development indicative of cell viability was measured by absorbance at 450 nm in a plate reader (Bio-rad).
PAH stability
In cell culture, TsA201 cells were kept as indicated for the HepG2 cell line. 1.5 × 10 5 cells per well were seeded in 24 well plates, grown overnight and transfected with 0.5 mg of pDEST-PAH or pDEST-PAHV106A plasmid DNA per well and the transfection reagent Primefect (Polyplus). Six hours after transfection 1 mM Phe was added to the culture media in order to simulate hyperphenylalaninemic conditions. After 18 h, the cells were incubated with the compounds or the media control during 1 h and the protein translation was stopped by addition of 10 mg/ml of puromycin. After 6 h, the cells were collected and lysed in SEC buffer with 1% Triton X and proteinase inhibitors (Roche). The cell debris were removed by centrifugation at 48C (10 4 g) and 100 mg of the cell lysates were analysed by SDS-PAGE on 10% polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Peqlab). Immunoblotting was done with goat anti-PAH, donkey anti-goat horseradish peroxidase (HRP)-conjugated secondary antibody (Sta. Cruz Biotechnology) and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH)-HRP (Sigma Aldrich). Finally, chemiluminescence detection was carried out by Immobilon western reagent (Millipore) and the heterologous protein expression was quantified relative to the protein expression controls using the freeware 'ImageJ'.
Proteinase digestion of recombinant PAH: per reaction, 15 mg of purified recombinant MBP-PAHV106A were preincubated with the compounds or control solvent at 48C for 30 min. Next 25 ng of ProteinaseK (Roth) were added. Following incubation for 90 s at 378C, the proteolysis was stopped by addition of SDS buffer and by boiling at 958C for 5 min. The different reactions were run onto 12% SDS-PAGE gels; silver stained and the degradation products were quantified with ImageJ.
Animals
Pah enu1 (BTBR.Cg-Pah enu1 /J) mice (30) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The animals were housed under controlled temperature conditions and kept on the basis of a cycle of 12 h light/dark period.
Between experiments, water and food were available ad libitum. All blood samples were taken from the tail and collected on filtre cards. Animal experiments were approved by the Austrian Ministry of Science. Tests were carried out in adult animals at age between 3 and 6 months.
L-[1-13]C-Phe breath test and blood sampling
The L-[1-13]C-Phe breath tests were performed as described (22, 46) . Sampling time was shortened to 86 min in order to reduce the mice's stress. The cumulative recovery of 13 C was calculated based on the ratio of 13 CO 2 to 12 CO 2 as previously described (47) , assuming a total CO 2 production rate of 94 ml per minute per g body weight × m 2 body surface area (70) . For the quantification of Phe, 40 ml of blood was taken from the tail vein and collected on filtre cards. Blood Phe was quantified by electron spray ionization-tandem mass spectrometry.
Single dose and 3-day treatment
The compounds were dissolved in DMSO or water to a concentration of 2 mg/ml and injected as either a single dose or as doses of 10 mg/g body weight on three consecutive days. Two hours after the last injection, the breath test was performed and blood was taken thereafter. As a control, the solvent (DMSO or water 5 ml/g body weight) was injected.
During and after the test, the animals were observed for any signs of toxicity, with special attention paid to weight loss, automutilation, tumours, abnormal movements or breathing, tremors, signs of ascites or centralized circulation.
Statistics
Statistical analyses were performed using GraphPadPrism (GraphPad Software, San Diego, CA, USA). Group mean values were compared by one-way analysis of variance (ANOVA) applying the Dunnet's multi-comparison test or the unpaired Student's t-test in cases of analysing two groups only.
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